$Predictors of Poor Response to Salvage Chemotherapy in Relapsed/ Refractory Pediatric Hodgkin Lymphoma- A Retrospective Analysis from Tertiary Cancer Centre in India$

Predictors of Poor Response to Salvage Chemotherapy in Relapsed/ Refractory Pediatric Hodgkin Lymphoma- A Retrospective Analysis from Tertiary Cancer Centre in India

Background: Previous studies identified prognostic factors for survival in relapsed pediatric Hodgkin lymphoma (HL) who received salvage chemotherapy followed by autologous stem cell transplant (ASCT). However, data regarding predictors of poor response to salvage chemotherapy is limited....

Full description

Bibliographic Details
Main Authors:	Sainath Bhethanabhotla, Sreenivas Vishnubhatla, Sameer Bakhshi
Format:	Article
Language:	English
Published:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2018-07-01
Series:	Annals of the National Academy of Medical Sciences (India)
Subjects:	relapsed hodgkin lymphoma risk factor poor response
Online Access:	http://www.thieme-connect.de/DOI/DOI?10.1055/s-0040-1712842

Similar Items

GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study
by: Mani Ramzi, et al.
Published: (2015-03-01)

Relapse of Hodgkin's disease revealed by skin involvement
by: Ouadii Abakarim, et al.
Published: (2022-09-01)

Salvage chemotherapy for adults with relapsed or refractory lymphoma in Malawi
by: Bongani Kaimila, et al.
Published: (2017-08-01)

CLINICAL CHARACTERISTICS AND TREATMENT RESULTS OF PEDIATRIC RELAPSED/REFRACTORY NON-HODGKIN’S LYMPHOMAS
by: T. T. Valiev
Published: (2018-07-01)

Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma
by: Valiollah Mehrzad, et al.
Published: (2017-01-01)

TARGETED THERAPY WITH BRENTUXIMAB VEDOTIN IN RELAPSED AND REFRACTORY FORMS OF CLASSICAL HODGKIN LYMPHOMA
by: E. A. Demina
Published: (2017-11-01)

Assessment of Effectiveness and Adverse Effect of New Combination Chemotherapy (irinotecan, cisplatin, and dexamethasone) in Relapse and Refractory Hodgkin Lymphoma
by: Mahdi Tabarraee, et al.
Published: (2023-07-01)

Modern approaches in relapsed and refractory Hodgkin lymphoma treatment: literature review and own experience
by: Natalia S. Tsaplina, et al.
Published: (2022-11-01)

TREATMENT OF RELAPSE AND REFRACTORY HODGKIN LYMPHOMA
by: E. A. Baryakh
Published: (2017-06-01)

The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
by: Jeremy A. Meier, et al.
Published: (2022-02-01)

Management of Relapsed Hodgkin Lymphoma During the Second Trimester of Pregnancy: Case Report
by: Fatih Yaman, et al.
Published: (2023-03-01)

Gemcitabina e ifosfamida no tratamento do linfoma de Hodgkin refratário ou recidivado após múltiplas terapias Gemcitabine and ifosfamide in the treatment of Hodgkin's lymphoma refractory to or relapsed after multiple therapies
by: Luís Fernando Pracchia, et al.
Published: (2007-12-01)

Salvage radiotherapy for relapsed/refractory non‐Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy
by: Nikhil Yegya-Raman, et al.
Published: (2023-03-01)

Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma
by: Patrick B. Johnston, et al.
Published: (2018-05-01)

Immunotoxin – a new treatment option in patients with relapsed and refractory Hodgkin lymphoma
by: Novakovic Barbara Jezersek
Published: (2015-12-01)

IEV (Ifosfamide, Epirubicin, VP16) Regimen as Salvage Therapy for Early Relapsed/Refractory non-Hodgkin/Hodgkin Lymphoma
by: Mohammadali Mashhadi, et al.
Published: (2011-09-01)

IEV (Ifosfamide, Epirubicin, VP16) Regimen as Salvage Therapy for Early Relapsed/Refractory non-Hodgkin/Hodgkin Lymphoma
by: Behrooz Najafi, et al.
Published: (2011-10-01)

Novel Agents For Relapsed and Refractory Classical Hodgkin Lymphoma: A Review
by: Yujie Zhang, et al.
Published: (2022-07-01)

Outcome of High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma after Different Numbers of Salvage Regimens
by: Jacopo Mariotti, et al.
Published: (2024-01-01)

Non-Hodgkin lymphoma with relapses in the lacrimal glands
by: Couceiro, Rita, et al.
Published: (2015-06-01)

Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy
by: Michael P. Randall, et al.
Published: (2023-09-01)

Novel Salvage Therapy Options for Initial Treatment of Relapsed/Refractory Classical Hodgkin’s Lymphoma: So Many Options, How to Choose?
by: Radhika Takiar, et al.
Published: (2022-07-01)

Nivolumab in relapsed/refractory Hodgkin Lymphoma patients, single center experiences
by: Ramazan Acar, et al.
Published: (2020-12-01)

Immunosuppressive Microenvironment and Efficacy of PD-1 Inhibitors in Relapsed/Refractory Classic Hodgkin Lymphoma: Checkpoint Molecules Landscape and Macrophage Populations
by: Artem Gusak, et al.
Published: (2021-11-01)

Brentuximab vedotin in the treatment of relapsed and refractory forms of Hodgkin lymphoma
by: E A Demina
Published: (2016-06-01)

Targeted therapy and hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma in pediatric and adolescent patients: a pilot protocol results
by: Natalia S. Tsaplina, et al.
Published: (2023-05-01)

Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma
by: Shinichi Makita, et al.
Published: (2022-12-01)

Real World Evidence of CAR T-Cell Therapies for the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: A Monocentric Experience
by: Beatrice Casadei, et al.
Published: (2021-09-01)

Evaluation of Prognostic Variables on Time to Relapse In Patients with Hodgkin's Lymphoma Using Classified Cox Model
by: Amir Elhaei, et al.
Published: (2019-12-01)

Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission
by: Kana Nagashima, et al.
Published: (2020-03-01)

Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents
by: Muhammad Salman Faisal, et al.
Published: (2023-04-01)

Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies
by: Karantanos T, et al.
Published: (2017-05-01)

The outcome of relapsed/refractory hodgkin's lymphoma patients post autologous bone marrow transplantation in a Baghdad Medical City Complex Center
by: Maryam Abdhlkadhum, et al.
Published: (2021-01-01)

Stem-Cell Transplantation in Adult Patients with Relapsed/Refractory Hodgkin Lymphoma
by: Sonja Genadieva Stavrik, et al.
Published: (2021-10-01)

Evaluation of the Relapse Risk and Survival Rate in Patients with Hodgkin Lymphoma: A Monocentric Experience
by: Ovidiu Potre, et al.
Published: (2021-09-01)

A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma
by: Walter Hanel, et al.
Published: (2023-02-01)

Effectiveness of chemotherapy after anti‐PD‐1 blockade failure for relapsed and refractory Hodgkin lymphoma
by: Beatrice Casadei, et al.
Published: (2020-11-01)

Salvage Therapy for Hodgkin’s Lymphoma: A Review of Current Regimens and Outcomes
by: Castagna L, et al.
Published: (2020-10-01)

Study of a metronomic-chemotherapy regimen comprising prednisone, etoposide and procarbazine combined with thalidomide±Rituxan for relapsed refractory B-cell lymphoma
by: Ke Lian, et al.
Published: (2023-05-01)

Everolimus as a single agent in refractory or relapsed Hodgkin's lymphoma: the Brazilian Named Patient Program Experience
by: Talita Máira Bueno da Silveira da Rocha, et al.